Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 7
2010 6
2011 2
2012 3
2013 5
2014 7
2015 6
2016 1
2017 1
2019 2
2020 1
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Novel therapeutic targets for multiple myeloma.
Mahindra A, Cirstea D, Raje N. Mahindra A, et al. Among authors: cirstea d. Future Oncol. 2010 Mar;6(3):407-18. doi: 10.2217/fon.10.2. Future Oncol. 2010. PMID: 20222797 Review.
CSNK1α1 mediates malignant plasma cell survival.
Hu Y, Song W, Cirstea D, Lu D, Munshi NC, Anderson KC. Hu Y, et al. Among authors: cirstea d. Leukemia. 2015 Feb;29(2):474-82. doi: 10.1038/leu.2014.202. Epub 2014 Jun 25. Leukemia. 2015. PMID: 24962017 Free PMC article.
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.
Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, Rivero G, Zimolzak A, Pyarajan S, Do N, Brophy M, Munshi NC. Fillmore NR, et al. Among authors: cirstea d. Blood. 2019 Jun 13;133(24):2615-2618. doi: 10.1182/blood.2019000406. Epub 2019 Apr 19. Blood. 2019. PMID: 31003998 Free PMC article. No abstract available.
Role of decorin in multiple myeloma (MM) bone marrow microenvironment.
Nemani N, Santo L, Eda H, Cirstea D, Mishima Y, Patel C, O'Donnell E, Yee A, Raje N. Nemani N, et al. Among authors: cirstea d. J Bone Miner Res. 2015 Mar;30(3):465-70. doi: 10.1002/jbmr.2371. J Bone Miner Res. 2015. PMID: 25407518 Free article.
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC. Suzuki R, et al. Among authors: cirstea d. Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300. Epub 2014 Oct 13. Leukemia. 2015. PMID: 25306900 Free PMC article. No abstract available.
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC. Minami J, et al. Among authors: cirstea d. Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub 2013 Aug 5. Leukemia. 2014. PMID: 23913134 Free PMC article.
43 results